Search PubMed⌕ Search

Biomedical subjects

T Nishimura

Publications and source records attributed to T Nishimura.

At least 1,081 records · Page 60Linked to original sources
PubMed1988

Endoscopic diagnosis and treatment of Dieulafoy's ulcer.

Dieulafoy's ulcer often develops unmanageable severe gastrointestinal hemorrhage and sometimes takes a fatal course. In the past surgical operations were considered to be the only life-saving measure for this lesion. Since 1979, 46 lesions of Dieulafoy's ulcer in 45 cases with active bleeding from exposed blood vessels were treated during emergency endoscopy by the hemostatic method of pure ethanol injection. Transient hemostasis was obtained in all cases. Rebleeding occurred in 5 cases (11%) and pure ethanol injection was performed again. Hemostasis was obtained in all cases, but one case again had rebleeding due to an overlooked Dieulafoy's ulcer located in the gastric fundus. Emergent surgical operation was performed in this case. No case required elective surgery and no deaths were attributed to bleeding. Our method achieved complete hemostasis at a rate of 98% (44 cases) for Dieulafoy's ulcer. The pure ethanol injection method is one of the most effective hemostatic methods for the Dieulafoy's ulcer.

Adult↗
PubMed1988

Efficacy of absolute ethanol injection for upper gastrointestinal massive bleedings with hemorrhagic shock.

We applied the absolute ethanol injection method in 182 cases of massive bleeding with hemorrhagic shock before the performance of emergency endoscopy in 627 cases of upper gastrointestinal bleeding at our department and five related institutions since June 1979. Following results were obtained: Temporary hemostasis could not be obtained in only 2 (1.1%) out of 182 cases; in the remaining 180 cases bleeding was ceased. Rebleeding was seen in 15 cases (8.2%) and new bleeding in 17 cases (9.3%). In 21 (66%) of these cases hemostasis was obtained again by the absolute ethanol injection method. Eight patients (4.4%) underwent emergency operation and 4 patients (2.2%) died from bleeding. The complete hemostasis was obtained in 170 cases (93.4%).

Adolescent↗
PubMed1988

The role of natural killer cells in human tonsillar tissue focussing on the change of tonsillar tissue with aging.

The natural killer (NK) activity of tonsillar lymphocytes is low and NK-cells are small in number. In tonsillar tissue, NK-cells were present in the germinal center, which is where B-cells are located. This suggests that B-cells are related to NK-cells. Judging from the rates of augmentation of NK-activity of INF-alpha, INF-beta, and from the fact that there is no difference in the rate of NK-activity augmentation between tonsillar and peripheral blood lymphocytes with IFN added, it is highly unlikely that there is much difference between the ratios of pre-NK cells and NK-cells. The fact that the NK-activity augmentation in the tonsil rose to approximately double that of peripheral blood on the addition of IL-2 suggests that the percentage of immature NK-cells is high in the tonsil. This supposition is in agreement with the morphological findings. In the infected and child tonsil, it is probable that NK-cells are at an immature stage, that NK-activity is low, that B-cells are active, and that immunoglobulin production is in progress.

Adult↗
PubMed1988

Experimental changes resembling the pathology of drusen in Bruch's membrane in the rabbit.

Drusen-like changes in Bruch's membrane following subretinal injection of vitreous in the rabbit were studied by electron microscopy. A sequence of changes is seen that closely panellels those observed during drusen formation in primates. The initial event is the budding of retinal pigment epithelial (RPE) cells into Bruch's membrane; the buds, which contain cytoplasm and plasma membrane, are connected to the cytoplasm of the parent RPE cell. Most buds are surrounded by basement membrane, but some penetrate RPE basement membrane into Bruch's membrane. Later, RPE buds completely separate from the parent RPE cell and show degeneration and disintegration. Finally, drusen-like material, including vesicular, granular, tubular and linear structures, is dispersed from the bud remnant into Bruch's membrane. The study described herein thus supports the hypothesis that drusen are the result of budding from the RPE.

Animals↗
PubMed1988

The avian cellular homolog of the oncogene jun.

We have isolated chicken genomic and cDNA clones representing the jun oncogene of avian sarcoma virus 17 (ASV17). The genomic clone lacks intron sequences within its protein coding domain, contains a CAAT box, seven SP-1 consensus sequences and TATA box-like elements upstream and two poly(A) addition signals downstream of the coding domain. The cellular jun protein is 310 amino acids in length. Cellular and viral jun proteins differ by three nonconservative amino acid substitutions of which two are located in the DNA-binding domain, by a 27-amino-acid deletion in the amino terminal third of the viral jun protein, by eleven cell-coded amino acids that link the cellular jun coding domain to the viral gag domain and by the partial gag sequences constituting the amino terminal of the viral gag-jun fusion protein. The availability of a cellular jun cDNA now allows the construction of reciprocal recombinants between the viral and the cellular gene which will define the structural features required for the oncogenicity of v-jun.

Amino Acid Sequence↗
PubMed1988

[Laboratory and clinical studies of rokitamycin in pediatric fields].

We have carried out laboratory and clinical studies on rokitamycin (RKM, TMS-19-Q). The results are summarized as follows. Serum and urinary concentrations of RKM were determined in 6 children with ages between 6 and 12 years given single oral doses of 5, 10 and 15 mg/kg. Mean serum concentrations peaked at 30 minutes after administration of 5, 10 and 15 mg/kg, and respective peak values were 0.30 microgram/ml, 0.79 microgram/ml and 1.32 micrograms/ml. Biological half-lives for 5, 10 and 15 mg/kg were 2.0 hours, 1.65 hours and 1.36 hours. The 6-hour urinary recovery ranged from 1.11% to 2.58% after administration of 5 mg/kg, and the mean 6-hour urinary recoveries were 1.35% after administration of 10 mg/kg and 2.28% after administration of 15 mg/kg. Therapeutic responses were recorded as excellent or good in 22 (73.3%) of the children, comprising 6 with tonsillitis, 2 with pharyngitis, 4 with bronchitis, 1 with bronchopneumonia, 1 with Mycoplasma pneumonia, 2 with whooping cough, 5 with streptococcal infections, 5 with Campylobacter enteritis, 3 with impetigo and 1 with SSSS. The microbiological effectiveness of RKM on identified pathogens comprising 4 strains of Staphylococcus aureus, 1 strain of Streptococcus pneumoniae, 6 strains of Streptococcus pyogenes, 4 strains of Haemophilus influenzae and 5 strains of Campylobacter spp. was not so satisfactory as evidenced by a eradication rate of 50.0%. No significant side effect due to the drug was observed in any cases. In conclusion, RKM was found to be efficacious and safe for the treatment of bacterial infections in children.

Administration, Oral↗
PubMed1988

[Pharmacokinetic and clinical studies on the use of ceftizoxime in premature and newborn infants. The Chemotherapy Research Group for Mother and Child].

A pharmacokinetic and clinical study of ceftizoxime (CZX), a newly developed cephem antibiotic intended for parenteral use, was conducted in premature and newborn infants, and resulted in the following findings. 1. Pharmacokinetics (1) Average serum half-lives (T 1/2) following a one shot intravenous dose of 20 mg/kg of CZX to mature and premature newborn infants in age groups of 0-3, 4-7, 8-14, and 15-30 days were: 4.14, 3.01, 2.57, and 1.98 hours (for mature infants) and 5.26, 4.59, 3.71, and 2.64 hours (for premature infants), respectively, decreasing with ages in days of the infants. (2) Average T 1/2's after a one shot 10 mg/kg dose was similar to that after a 20 mg/kg dose. Serum concentrations of CZX were dose-dependent. (3) T 1/2 after 1-hour intravenous drip infusion revealed a same trend after one shot injection. (4) Urinary in the first approximately 6 hours recoveries following a 20 mg/kg one shot dose to mature and premature newborn infants were as follows: 35% (0-3 days old) and 45-55% (4 days old and older) in mature infants and 30% (0-3 days old) and 45% (4 days old and older) in premature infants. 2. Therapeutic effectiveness (1) The subjects examined were 112 newborn infants consisting of 83 with infections and 29 who received CZX for prophylaxis. The 83 infants had 86 cases of infections, which were classified as A, when the causative organisms were identified and as B, when the causative organisms were not identified. Rates of therapeutic effectiveness were 95.0% for group A and 95.7% for group B. Bacteriological effectiveness were studied on 41 strains isolated from group A, and were as high as 89.5% for Gram-positive organisms and 95.5% for Gram-negative organisms. The rate of successful prophylaxis for the 29 infants was 96.6%. (2) Side effects did not occur among the 120 newborn infants. Laboratory tests with abnormalities included leukopenia, neutropenia, eosinophilia, thrombocytosis and increased GOT or GPT. These pharmacodynamic and clinical findings have fully substantiated the satisfactory therapeutic usefulness of CZX in both the treatment and prevention of neonatal infections in the usual dose of 20 mg/kg, which is to be given b.i.d. for infants up to 3 days old; b.i.d. or t.i.d. for infants 4 to 7 days old, and t.i.d. or q.i.d. for infants 8 days old and older. The drug can be given in a daily dose as high as 120 mg/kg when infection is severe.

Bacterial Infections↗